Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1754132 | 0.82 | ALDH1A1 (0.58) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL29998273 | 0.82 | ALDH1A1 (0.48) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL23458004 | 0.79 | ALDH1A1 (0.50) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL10966283 | 0.79 | SLC6A2 (0.48) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL25039216 | 0.77 | ALDH1A1 (0.52) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL228926 | 0.77 | SLC6A2 (0.67) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL7554001 | 0.75 | BLM (0.46) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| Hydrochloric Acid SCHEMBL5831539 | 0.75 | SLC6A2 (0.64) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL5708352 | 0.75 | SLC6A2 (0.64) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL10891421 | 0.75 | SLC6A2 (0.64) | SLC6A2HTR2ASLC6A4HRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0146067-A2 | Novel substrates for D-amino acid oxidase | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-06-26 | — | — | EP | claimed |
| US-20120041041-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG | 2012-02-16 | — | — | US | disclosed |
| US-8076489-B2 | 3H-benzothiazol-2-one derivatives, for example, (R)-7-[2-(1,1-dimethyl-2-phenyl-ethylamino)-1-hydroxy-ethyl]-5-hydroxy-3H-benzothiazol-2-one; useful for treating conditions that are prevented or alleviated by activation of the beta 2-adrenoreceptor | NOVARTIS AG (CH) | 2011-12-13 | — | — | US | disclosed |
| EP-1819686-B1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| EP-2305659-A1 | 5-hydroxy-benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20080096940-A1 | 5-Hydroxy-Benzothiazole Derivatives Having Beta-2-Adrenoreceptor Agonist Activity | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| EP-1819686-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECPTOR AGONIST ACTIVITY | Novartis AG (CH) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006056471-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-01 | — | — | WO | disclosed |
| US-20050137242-A1 | Betamimetics having a long-lasting activity, processes for preparing them, and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-06-23 | — | — | US | disclosed |
| EP-1305300-A1 | NOVEL, SLOW-ACTING BETAMIMETICS, A METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-05-02 | — | — | EP | disclosed |
| US-20020022625-A1 | Betamimetics having a long-lasting activity, processes for preparing them, and their use as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-02-21 | — | — | US | disclosed |
| WO-2001083462-A1 | NOVEL, SLOW-ACTING BETAMIMETICS, A METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-08 | — | — | WO | disclosed |
| EP-0146067-A2 | Novel substrates for D-amino acid oxidase | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137242-A1 | Betamimetics having a long-lasting activity, processes for preparing them, and their use as medicaments | CHRM1, ADRB1, ADRB3 | SLC6A2 142/4885HTR2A 629/4885SLC6A4 267/4885 |
| US-20020022625-A1 | Betamimetics having a long-lasting activity, processes for preparing them, and their use as medicaments | ADRB2, ADRB3, ADRB1 | SLC6A2 151/4885HTR2A 674/4885SLC6A4 250/4885 |
| US-20120041041-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | SLC6A2 162/4885HTR2A 32/4885SLC6A4 487/4885 |
| US-20080096940-A1 | 5-Hydroxy-Benzothiazole Derivatives Having Beta-2-Adrenoreceptor Agonist Activity | ADRB2, ADRB1, ADRA2C | SLC6A2 162/4885HTR2A 32/4885SLC6A4 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.